Brief Summary
The proposed IMPOWR Research Center at Montefiore-Einstein (IMPOWR-ME) will create a multidisciplinary and synergistic program of research to test multimodal treatments that address both chronic pain and opioid use disorder. IMPOWR-ME will generate critical knowledge about the effectiveness, implementation, and cost effectiveness of providing Acceptance and Commitment Therapy and/or a care management smartphone app for individuals in primary care-based buprenorphine treatment. Patients with lived experience with chronic pain and/or opioid use disorder, patient and policy advocates, payors, and health system partners will be engaged in all stages of the research. IMPOWR-ME is well-positioned to become a long-lasting hub for stakeholder-engaged research with multidisciplinary senior and early stage investigators focused on reducing overdose through better treatments for OUD and CP.
Brief Title
Randomized Trial of ACT and a Care Management App in Primary Care-based Buprenorphine Treatment
Detailed Description
Chronic pain (CP) and opioid use disorder (OUD) are leading causes of morbidity and mortality in the United States. Despite being commonly comorbid, there is a striking lack of integrated treatments accessible to people in need. This is particularly true for Black and Hispanic individuals living and seeking care in under-resourced settings like The Bronx, NY, one of the poorest and most racially diverse counties in the U.S. Submitted in response to the HEAL Initiative: Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR) RFA-DA-21-030, the overall goal of this proposal is to create the IMPOWR Research Center at Montefiore/Einstein ("IMPOWR-ME"), in the high-impact county of The Bronx NY. IMPOWR-ME is a synergistic multidisciplinary research center that leverages exceptional research infrastructure in CP and OUD and existing relationships with people living with CP and OUD, advocates, policymakers and payers, and health system stakeholders. The aims of IMPOWR-ME are to: 1) create a robust and sustainable research infrastructure to rigorously test and disseminate integrated and cost-effective evidence-based practices for people with CP and OUD; 2) partner with people with lived experience with CP, OUD, or both, and diverse stakeholders in all stages of the research; and 3) provide opportunities for multidisciplinary early stage investigators to become independent researchers focusing on CP and OUD. This innovative hybrid type 1 effectiveness-implementation trial is proposed to rigorously examine multi-modal evidence-based practices in diverse health care settings and populations of people with comorbid CP and OUD. Specifically, the investigators propose a 2x2 factorial trial to test Acceptance and Commitment Therapy and a care management smartphone app for individuals in primary-care based buprenorphine treatment. Participants will have both CP and OUD or opioid misuse, and specific aims will examine CP, OUD, implementation, and cost-effectiveness outcomes; additional patient-centered outcomes will be driven by people with lived experience. This project improves access to care for Black and Hispanic individuals in under-resourced settings by bringing integrated treatment of CP and OUD to them, and the interventions have high potential for dissemination and sustainability. An innovative program for pilot studies achieves a dual aim of catalyzing stakeholder-driven research and training early stage and new investigators. An exceptional team of investigators and clinical experts focused on CP and OUD, a longstanding history of collaboration with stakeholders and people with lived experience, and a high-impact population make Montefiore-Einstein an ideal site for an IMPOWR research center.
Categories
Central Contacts
Central Contact Role
Contact
Central Contact Phone
718-683-0213
Central Contact Email
heperez@montefiore.org
Central Contact Role
Contact
Central Contact Email
joanna.starrels@einsteinmed.edu
Completion Date
Completion Date Type
Estimated
Conditions
Opioid-use Disorder
Chronic Pain
Eligibility Criteria
Inclusion Criteria:
1. 18 years old or older;
2. English or Spanish proficiency;
3. receiving BUP treatment for OUD for at least 14 days (thus a stabilized BUP dose); and
4. CP with at least moderate pain severity (score greater than or equal to 4 on Pain, Enjoyment of Life and General Activity scale (PEG). Comorbid psychiatric conditions and use of psychotropic medications will be allowed.
Exclusion Criteria:
1. Acute exacerbation of psychiatric conditions precluding the ability to participate in the study (e.g., acute mania, active suicidality/homicidality, psychosis);
2. psychotropic medication changes within the past three months prior to enrollment;
3. CP related to malignancy;
4. received ACT or similar therapeutic intervention in the past;
5. initiated psychotherapy within the past three months;
6. neurocognitive conditions that may prevent participants from accessing telehealth services;
7. current use of a smartphone health platform similar to the Valera app;
8. are unable or unwilling to provide signed consent for participation.
1. 18 years old or older;
2. English or Spanish proficiency;
3. receiving BUP treatment for OUD for at least 14 days (thus a stabilized BUP dose); and
4. CP with at least moderate pain severity (score greater than or equal to 4 on Pain, Enjoyment of Life and General Activity scale (PEG). Comorbid psychiatric conditions and use of psychotropic medications will be allowed.
Exclusion Criteria:
1. Acute exacerbation of psychiatric conditions precluding the ability to participate in the study (e.g., acute mania, active suicidality/homicidality, psychosis);
2. psychotropic medication changes within the past three months prior to enrollment;
3. CP related to malignancy;
4. received ACT or similar therapeutic intervention in the past;
5. initiated psychotherapy within the past three months;
6. neurocognitive conditions that may prevent participants from accessing telehealth services;
7. current use of a smartphone health platform similar to the Valera app;
8. are unable or unwilling to provide signed consent for participation.
Inclusion Criteria
Inclusion Criteria:
1. 18 years old or older;
2. English or Spanish proficiency;
3. receiving BUP treatment for OUD for at least 14 days (thus a stabilized BUP dose); and
4. CP with at least moderate pain severity (score greater than or equal to 4 on Pain, Enjoyment of Life and General Activity scale (PEG). Comorbid psychiatric conditions and use of psychotropic medications will be allowed.
1. 18 years old or older;
2. English or Spanish proficiency;
3. receiving BUP treatment for OUD for at least 14 days (thus a stabilized BUP dose); and
4. CP with at least moderate pain severity (score greater than or equal to 4 on Pain, Enjoyment of Life and General Activity scale (PEG). Comorbid psychiatric conditions and use of psychotropic medications will be allowed.
Gender
All
Gender Based
false
Healthy Volunteers
No
Last Update Post Date
Last Update Post Date Type
Actual
Last Update Submit Date
Minimum Age
18 Years
NCT Id
NCT05039554
Org Class
Other
Org Full Name
Albert Einstein College of Medicine
Org Study Id
2021-13325
Overall Status
Recruiting
Phases
Not Applicable
Primary Completion Date
Primary Completion Date Type
Estimated
Official Title
Randomized Trial of Acceptance and Commitment Therapy (ACT) and a Care Management App in Primary Care-based Buprenorphine Treatment
Primary Outcomes
Outcome Description
The primary outcome for pain will be pain-related functional interference, assessed with the Brief Pain Inventory (BPI), pain interference subscale, a nine-item measure that assesses pain related interference with general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. The total score has demonstrated reliability (e.g., Cronbach's Alpha = 0.86) and validity with chronic pain patients.
Outcome Measure
Pain interference
Outcome Time Frame
Baseline, 30 days, 12 weeks, 36 weeks
Outcome Description
Opioid use will be measures by the Addiction Severity Index (ASI), which provides an assessment of drug use in the past 30 days, as done in our other studies.
Outcome Measure
Opioid Use
Outcome Time Frame
Baseline, 30 days, 6 weeks, 12 weeks, 24 weeks, 36 weeks
Secondary Ids
Secondary Id
RM1DA055437
Secondary Outcomes
Outcome Description
Quality of life based on Physical, Emotional, and Substance Use
Outcome Time Frame
Baseline, 12 weeks, 24 weeks, 36 weeks
Outcome Measure
Patient Report Outcome Measurement
Outcome Description
psychological flexibility of behavior, feelings and emotions
Outcome Time Frame
Baseline, 30 days, 6 weeks, 12 weeks, 24 weeks, 36 weeks
Outcome Measure
Multidimensional Psychological Flexibility Inventory (MPFI)
Outcome Description
Feelings of pain and whether they can be accepted or tolerated
Outcome Time Frame
Baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks
Outcome Measure
CHRONIC PAIN ACCEPTANCE QUESTIONNAIRE
Outcome Description
Substance use urges and psychological flexibility when it comes to misuse
Outcome Time Frame
Baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks
Outcome Measure
AAQ-SA
Outcome Description
Mood symptoms will be assessed by the Patient Health Questionnaire Beck Depression Inventory
Outcome Time Frame
Baseline, 30 days, 6 weeks, 12 weeks, 24 weeks, 36 weeks
Outcome Measure
Mood Symptoms
Outcome Description
Anxiety symptoms will be assessed by the Beck Anxiety Index
Outcome Time Frame
Baseline, 30 days, 6 weeks, 12 weeks, 24 weeks, 36 weeks
Outcome Measure
Anxiety Symptoms
Outcome Description
Pain catastrophizing will be assessed via the Pain Catastrophizing Scale.
Outcome Time Frame
Baseline, 12 weeks, 36 weeks
Outcome Measure
Pain catastrophizing
Outcome Description
Trauma will be assessed for via the Life Events Checklist.
Outcome Time Frame
Baseline and 24 weeks
Outcome Measure
Trauma
Outcome Description
Opioid craving will be assessed for via the Medication Craving Scale.
Outcome Time Frame
Baseline, 30 days, 6 weeks, 12 weeks, 24 weeks, 36 weeks
Outcome Measure
Opioid craving
Outcome Description
Substance use other than opioid use will be assessed via the ASI
Outcome Time Frame
Baseline, 30 days, 6 weeks, 12 weeks, 24 weeks, 36 weeks
Outcome Measure
Substance Use
Outcome Description
Audit C
Outcome Time Frame
Baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks
Outcome Measure
Alcohol Use
Outcome Description
urine toxicology tests.
Outcome Time Frame
Baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks
Outcome Measure
Substance use
Outcome Description
Anhedonia will be assessed via the Snaith-Hamilton Pleasure Scale (SHAPS).
Outcome Time Frame
Baseline, 24 weeks, 36 weeks
Outcome Measure
Anhedonia
Outcome Description
Sleep will be assessed via PROMIS Sleep Disturbance 6a + Sleep Duration Question.
Outcome Time Frame
Baseline, 12 weeks, 24 weeks, 36 weeks
Outcome Measure
Sleep
Outcome Description
NIH Toolbox Perceived Stress Fixed Form 18+.
Outcome Time Frame
Baseline, 12 weeks, 24 weeks, 36 weeks
Outcome Measure
Perceived Stress
Outcome Description
Stress will be assessed via the Urban Life Stress Scale.
Outcome Time Frame
Baseline and 24 weeks
Outcome Measure
Stress
Outcome Description
Stigma and discrimination will be assessed via the Perceived discrimination: Everyday discrimination scale.
Outcome Time Frame
Baseline
Outcome Measure
Stigma & discrimination
Outcome Description
Suicidality will be assessed via the Columbia Suicide Severity Rating Scale. CSSR-S
Outcome Time Frame
Baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks
Outcome Measure
Suicidality
Outcome Description
Satisfaction with therapy will be assessed by administration of a 13-item 'Satisfaction With Therapy Scale Revised' questionnaire. Responses to the items on the questionnaire will assess the participants' agreement to the various statements that best describe the ACT therapy received over the past 12 weeks based on a 5 point scale ranging from 1 ("Strongly disagree") to 5 ("Strongly agree") for an overall possible score of 13-65 with higher scores denoting increased satisfaction. Group scores will be summarized by study arm using basic descriptive statistics.
Outcome Time Frame
12 weeks
Outcome Measure
Satisfaction with Therapy
Start Date
Start Date Type
Actual
Status Verified Date
First Post Date
First Post Date Type
Actual
First Submit Date
First Submit QC Date
Std Ages
Adult
Older Adult
Maximum Age Number (converted to Years and rounded down)
999
Minimum Age Number (converted to Years and rounded down)
18
Investigators
Investigator Type
Principal Investigator
Investigator Name
Hector Perez
Investigator Email
heperez@montefiore.org